The mechanism of radiosensitization by YM155, a novel small molecule inhibitor of survivin expression, is associated with DNA damage repair

Cellular Physiology and Biochemistry

Volumn 37, Issue 3, 2015, Pages 1219-1230

  Hu, Songliu ^a   Fu, Songbin ^a   Xu, Xiangying ^a   Chen, Lin ^a   Xu, Jianyu ^a   Li, Bin ^b   Qu, Yuanyuan ^a   Yu, Hongyang ^a   Lu, Shan ^a   Li, Wenxin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

DNA repair; DNA PKcs; Ku70; Non small cell lung cancer; Phospho histone H2AX; Survivin

Indexed keywords

HISTONE H2AX; KU ANTIGEN; PROTEIN KINASE C; PROTEIN P53; RADIOSENSITIZING AGENT; SEPANTRONIUM BROMIDE; SURVIVIN; BIRC5 PROTEIN, HUMAN; H2AFX PROTEIN, HUMAN; HISTONE; IMIDAZOLE DERIVATIVE; INHIBITOR OF APOPTOSIS PROTEIN; NAPHTHOQUINONE;

ARTICLE; AUTOPHOSPHORYLATION; CELL FRACTIONATION; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLONOGENESIS; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG MECHANISM; FLOW CYTOMETRY; HISTONE PHOSPHORYLATION; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN VITRO STUDY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RADIOSENSITIZATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL NUCLEUS; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; PHOSPHORYLATION; RADIATION RESPONSE; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; NAPHTHOQUINONES; PHOSPHORYLATION; RADIATION-SENSITIZING AGENTS;

EID: 84945894549     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000430245     Document Type: Article

References (35)

1. Huang RY, Chu YL, Jiang Z.B., Chen XM, Zhang X, Zeng X: Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase. Cell Physiol Biochem 2014; 33:375-388.
2. Rodel F, Reichert S, Sprenger T., Gaipl US, Mirsch J, Liersch T, Fulda S., Rodel C: The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr Med Chem 2011; 18:191-199.
3. Church DN, Talbot DC: Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012; 14:120-128.
4. Chakravarti A, Zhai GG, Zhang M, Malhotra R., Latham DE, Delaney MA, Robe P, Nestler U., Song Q, Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004; 23:7494-7506.
5. Cheson BD, Bartlett NL, Vose J.M., Lopez-Hernandez A, Seiz AL, Keating A.T., Shamsili S., Papadopoulos KP: A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012; 118:3128-3134.
6. Tolcher AW, Quinn DI, Ferrari A, Ahmann F., Giaccone G, Drake T, Keating A., de Bono JS: A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol 2012; 23:968-973.
7. Lewis KD, Samlowski W, Ward J., Catlett J, Cranmer L, Kirkwood J., Lawson D, Whitman E, Gonzalez R: A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2011; 29:161-166.
8. Giaccone G, Zatloukal P, Roubec J., Floor K, Musil J, Kuta M., van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S: Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27:4481-4486.
9. Tolcher AW, Mita A, Lewis L.D., Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K., Takimoto C, Bartels P, Keating A., Antonia S.: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26:5198-5203.
10. Valerie K, Povirk LF: Regulation and mechanisms of mammalian double-strand break repair. Oncogene 2003; 22:5792-5812.
11. Lees-Miller S.P., Meek K: Repair of DNA double strand breaks by non-homologous end joining. Biochimie 2003; 85:1161-1173.
12. Celeste A, Fernandez-Capetillo O, Kruhlak M.J., Pilch DR, Staudt DW, Lee A, Bonner R.F., Bonner WM, Nussenzweig A: Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol 2003; 5:675-679.
13. Shiloh Y: ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-168.
14. Rodel F, Hoffmann J, Distel L., Herrmann M, Noisternig T, Papadopoulos T., Sauer R, Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005; 65:4881-4887.
15. Iwasa T, Okamoto I, Suzuki M., Nakahara T, Yamanaka K, Hatashita E., Yamada Y, Fukuoka M, Ono K., Nakagawa K: Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008; 14:6496-6504.
16. Hoffman WH, Biade S, Zilfou J.T., Chen J., Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-3257.
17. Mirza A, McGuirk M, Hockenberry T.N., Wu Q., Ashar H, Black S, Wen S.F., Wang L., Kirschmeier P, Bishop WR, Nielsen L.L., Pickett CB, Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21:2613-2622.
18. Riches LC, Lynch AM, Gooderham NJ: Early events in the mammalian response to DNA double-strand breaks. Mutagenesis 2008; 23:331-339.
19. Dohi T, Xia F, Altieri DC: Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell 2007; 27:17-28.
20. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett K.M., Tognin S., Marchisio PC, Altieri DC: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J Cell Sci 2002; 115:575-585.
21. Dohi T, Beltrami E, Wall N.R., Plescia J., Altieri DC: Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114:1117-1127.
22. Stauber RH, Mann W, Knauer SK: Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007; 67:5999-6002.
23. Connell CM, Colnaghi R, Wheatley SP: Nuclear survivin has reduced stability and is not cytoprotective. J Biol Chem 2008; 283:3289-3296.
24. Stauber RH, Rabenhorst U, Rekik A., Engels K, Bier C, Knauer SK: Nucleocytoplasmic shuttling and the biological activity of mouse survivin are regulated by an active nuclear export signal. Traffic 2006; 7:1461-1472.
25. Colnaghi R, Connell CM, Barrett R.M., Wheatley SP: Separating the anti-apoptotic and mitotic roles of survivin. J Biol Chem 2006; 281:33450-33456.
26. Knauer SK, Bier C, Habtemichael N., Stauber RH: The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. EMBO Rep 2006; 7:1259-1265.
27. Knauer SK, Kramer OH, Knosel T, Engels K., Rodel F, Kovacs AF, Dietmaier W, Klein-Hitpass L, Habtemichael N., Schweitzer A, Brieger J, Rödel C, Mann W., Petersen I, Heinzel T, Stauber RH: Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007; 21:207-216.
28. Ghosh JC, Dohi T, Raskett C.M., Kowalik TF, Altieri DC: Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res 2006; 66:11576-11579.
29. Capalbo G, Dittmann K, Weiss C., Reichert S, Hausmann E, Rodel C., Rodel F: Radiation-induced survivin nuclear accumulation is linked to DNA damage repair. Int J Radiat Oncol Biol Phys 2010; 77:226-234.
30. Li J, Xing M, Zhu M., Wang X, Wang M, Zhou S., Li N, Wu R, Zhou M: Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization. Cancer Lett 2008; 272:91-101.
31. Banath J.P., Macphail SH, Olive PL: Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 2004; 64:7144-7149.
32. Taneja N, Davis M, Choy J.S., Beckett MA, Singh R, Kron SJ, Weichselbaum RR: Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004; 279:2273-2280.
33. Peng Y, Zhang Q, Nagasawa H., Okayasu R, Liber HL, Bedford JS: Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiation-induced chromosome damage, cell killing, and mutation. Cancer Res 2002; 62:6400-6404.
34. Marangoni E, Foray N, O'Driscoll M, Douc-Rasy S, Bernier J., Bourhis J, Jeggo P: A Ku80 fragment with dominant negative activity imparts a radiosensitive phenotype to CHO-K1 cells. Nucleic Acids Res 2000; 28:4778-4782.
35. Chen BP, Uematsu N, Kobayashi J., Lerenthal Y, Krempler A, Yajima H., Lobrich M, Shiloh Y, Chen DJ: Ataxia telangiectasia mutated (ATM) is essential for DNA-PKcs phosphorylations at the Thr-2609 cluster upon DNA double strand break. J Biol Chem 2007; 282:6582-6587.